Prolylleucine-Benzyloxy-carbonyl-L-prolyl-D-leucine-DataSheet-生命科学试剂-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEProlylleucineCat. No.: HY-112173CAS No.: 61596-47-2Synonyms: (Benzyloxy)carbonyl)-L-prolyl-D-leucine分式: CHNO分量: 362.42Sequence: Z-Pro-d-LeuSequence Shortening: ZP-d-Leu作靶点: Others作通路: Others储存式: Powder -20C 3 yearsIn solvent -80

2、C 6 months-20C 1 month溶解性数据体外实验 DMSO : 100 mg/mL (275.92 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 2.7592 mL 13.7961 mL 27.5923 mL5 mM 0.5518 mL 2.7592 mL 5.5185 mL10 mM 0.2759 mL 1.3796 mL 2.7592 mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存式和期限。体内实验请

3、根据您的实验动物和给药式选择适当的溶解案，配制前请先配制澄清的储备液，再依次添加助溶剂(为保证实验结果的可靠性，体内实验的作液，建议您现现配，当天使；澄清的储备液可以根据储存条件，适当保存；以下溶剂前的百分 指该溶剂在您配制终溶液中的体积占)：1. 请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (6.90 mM); Clear solution1/2 Master of Small Molecules 您边的抑制剂师www.MedChemE2. 请依序添加每种溶剂： 10% DMSO 90%

4、 (20% SBE-CD in saline)Solubility: 2.5 mg/mL (6.90 mM); Clear solution3. 请依序添加每种溶剂： 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (6.90 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 Prolylleucine种含有链氨 酸的肽。体外研究 The addition of specific dipeptide containing branched-chain amino acids, such as Prolylleucine,

5、to thegrowth medium negatively affects cell envelope-associated proteinase (CEP) activity, whereas dipeptideswithout branched-chain amino acids had no effect on the enzymes production. To determine if certainpeptides are involved in the regulation of CEP biosynthesis, eight specific dipeptides, one

6、tripeptide, and twopeptide fractions (LMMP and HMMP) from Casitone are evaluated. The CEP activity levels of L. delbrueckiisubsp. lactis CRL 581 grown in MDM supplemented with LMMP are similar to those obtained in cells grownin minimal defined medium (MDM) supplemented with Casitone (99-fold reducti

7、on). The addition ofleucylglycylglycine (LGG), leucylleucine (LL), leucylproline (LP), or Prolylleucine (PL) (final concentration, 1mM) to MDM leads to a 6.5-, 7-, 4-, or 3.5-fold reduction in CEP activity, respectively. An increase of up to 5mM in the concentration of these dipeptides results in a

8、further two- or threefold reduction of CEP activitycompared to the activity obtained in the presence of 1 mM of the peptide mentioned above. LGG, LL, LP, andProlylleucine contain leucine as a branched-chain amino acid (BCAA). In contrast, no effect on CEP activityis observed by the supplementation o

9、f MDM with 1 to 5 mM of GT, PA, TG, GM, GP (dipeptides withoutBCAA), or HMMP. No inhibitory effect on proteinase activity from the presence of high concentrations (10-fold increase) of each of the 20 amino acids in the growth medium is observed. However, a 50-fold increasein BCAA concentration in MD

10、M leads to a repression of proteinase synthesis of 40%. L. delbrueckii subsp.lactis is auxotrophic for BCAA 1.户使本产品发表的科研献 Laurea Magistrale in Biomedical Engineering, Politecnico di Milano. 2019 Jun. bioRxiv. 2019 Jan.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Hebert EM, et al. Characterization of the pattern of alphas1- and beta-casein breakdown and release of a bioactive peptide by a cellenvelope proteinase from Lactobacillus delbrueckii subsp. lactis CRL 581. Appl Environ Microbiol. 2008 Jun;74(12):3682-9.McePdfHeightCaution: Product has not bee